Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2021-09-01 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
关于北京神州细胞生物技术集团股份公司向特定对象发行股票审核意见的通知
Capital/Financing Update Classification · 95% confidence The document is a notification from the Shanghai Stock Exchange's Science and Technology Innovation Board Listing Review Center regarding the review opinion on a company's application for a private placement of shares. It references regulatory laws and rules related to securities issuance and listing. The content focuses on the approval and conditions for a specific share issuance, including risk disclosures and compliance requirements. The document is short (477 characters) and serves as an official announcement of the review opinion rather than the detailed issuance report or financial data. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-09-01 Chinese
神州细胞关于收到向特定对象发行股票审核意见的通知公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the receipt of a review opinion from the Shanghai Stock Exchange on the company's application for a private placement of shares. It discusses the compliance of the issuance with regulatory requirements and the need for further responses before final registration by the China Securities Regulatory Commission. The document is short (697 characters) and serves as a notification about the status of a capital raising process rather than the detailed report or financial data itself. Therefore, it fits the category of a Capital/Financing Update (CAP).
2021-09-01 Chinese
普华永道中天会计师事务所（特殊普通合伙）关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的第二轮审核问询函的回复（2021半年报财务数据更新版）
Management Reports Classification · 95% confidence The document is a detailed response to inquiries regarding the use of IPO raised funds, progress of clinical research projects, and the necessity and predictability of new fundraising projects. It discusses specific clinical trial phases, funding usage, and project timelines, indicating it is a comprehensive management discussion and analysis of financial and operational progress related to fundraising and project implementation. There is no indication that this is a full annual or quarterly report, nor is it a simple announcement or certification. The content aligns with a Management Discussion and Analysis (MDA) report, which explains financial results, business trends, and outlook in detail.
2021-08-26 Chinese
关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的第三轮审核问询函的回复报告（2021半年报财务数据更新版）
Capital/Financing Update Classification · 95% confidence The document is a detailed reply report to a third-round inquiry letter from the Shanghai Stock Exchange regarding a company's application for a private placement of shares (向特定对象发行股票申请文件). It discusses the financing scale, project adjustments, investment details, risk analysis, and includes statements from the issuer and the sponsor institution. The content focuses on the company's capital raising activities, specifically the issuance of shares to specific investors and the use of proceeds for new drug R&D projects. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. Instead, it is a detailed regulatory filing related to capital raising and financing activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (12,430 characters) and detailed content support this classification with high confidence.
2021-08-26 Chinese
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2021年度向特定对象发行A股股票的补充法律意见书（二）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm (北京市金杜律师事务所) regarding a specific issuance of A shares by 北京神州细胞生物技术集团股份公司 in 2021. It references regulatory frameworks, securities laws, and specific inquiries from the Shanghai Stock Exchange related to the issuance. The document includes detailed legal verification and opinions on matters such as product approvals, commercial disputes, financial investments, and the legitimacy of subscription funds. It is not a financial report, earnings release, or management discussion but a legal opinion related to a capital raising event. This fits the category of Capital/Financing Update (CAP), as it pertains to the legal aspects of a specific financing transaction (private placement of A shares). The document length and content confirm it is the report itself, not just an announcement or certification, so it is not RPA or RNS.
2021-08-26 Chinese
普华永道中天会计师事务所（特殊普通合伙）关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的审核问询函的回复（2021半年报财务数据更新版）
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure regarding a company's fundraising plan, specifically a private placement of A shares with a total fundraising amount not exceeding 3,960,737,000 yuan. It discusses the use of proceeds for new drug R&D projects, marketing network construction, and replenishment of working capital. The text includes detailed financial tables, investment project breakdowns, accounting policies on capitalization of R&D expenses, and justifications for the proportion of non-capital expenditures. It also contains auditor's verification procedures and opinions, as well as comparisons with peer companies' asset structures and R&D investment rationales. The document is comprehensive, contains substantive financial data, investment project details, and auditor opinions related to the fundraising and capital use. It is not a brief announcement or a simple notice but a full report on the capital raising and investment plan with financial and operational analysis. Therefore, the document fits best into the category of Capital/Financing Update (CAP).
2021-08-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.